New £1-a-day drug slows the effect of arthritis
There are hopes that a revolutionary drug could be an effective treatment for arthritis after showing promise in clinical trials.
The qualities of strontium ranelate, which is otherwise known as Protelos, means it is already used as a treatment for the brittle bone disease osteoporosis.
But it is now thought the drug could also help to slow and minimise the effects of osteoarthritis (OA), one of the most common forms of arthritis.
This would make Protelos the first drug in the world to do so and the good news is that is costs less than £1 a day.
To read the latest edition of Healthcare Global, click here
- EMRs help to keep costs down, say struggling hospitals
- Budget 2012: GSK invests £500m in UK drug manufacturing
- Robot completes first bladder construction
OA is a particularly crippling form of arthritis, which causes cartilage and bones to wear away in the joints, leading to extreme pain and discomfort.
Until now, there have been no treatments that can slow the progression of OA; only physiotherapy and pain management therapies have been available.
The condition frequently results in patients needing hip and knee replacements too.
However, a study that was carried out over a period of three years revealed Protelos was able to reduce the deterioration of cartilage in the knees by up to a third.
The patients taking a two milligram dose of the drug also experienced a reduction in pain and increased mobility.
It was therefore concluded that if patients took Protelos for three years, the progression of osteoarthritis would be slowed by a year.
Professor Cyrus Cooper, who presented the findings of the study in France at the European Congress on Osteoporosis and Osteoarthritis (ECCEO) was excited by the drug’s potential.
"This is a major breakthrough,” he said.
“Osteoarthritis is a painful and debilitating condition and for over 20 years we have been searching for a treatment that would allow us to alter the course of the disease, rather than just manage the symptoms.”
Cooper added: “The results today are it and could totally change the way we treat osteoarthritis.
“For the first time we have a treatment that can slow the development of this debilitating disease and could reduce or even eliminate the need for expensive and painful joint replacement surgery.”
As opposed to being an oral pill, Protelos comes in a lemon-flavoured powder form which is mixed with water which should be taken just before going to sleep.
French pharmaceutical manufacturer Servier is now applying for a licence stating the drug is a successful treatment for both osteoarthritiss and osteoporosis.
The Healthcare Global magazine is now available on the iPad. Click here to download it.
Dubai's new smart neuro spinal hospital: need to know
We take a look at Dubai's new smart hospital.
What: The Neuro Spinal Hospital and Radiosurgery Centre is a new hospital featuring state-of-the-art technology for spinal, neurosurgical, neurological, orthopaedic, radiosurgery and cancer treatments. The 700 million AED hospital, (equivalent to £138 million), has 114 beds, smart patient rooms, and green spaces for patient rehabilitation, and is four times the capacity of its former premises in Jumeirah. It is also the UAE’s first hospital to have surgical robots.
Where: The hospital is located in the Dubai Science Park. Founded in 2005, Dubai Science Park is home to more than 350 companies from multinational corporations in life sciences, biotechnology and research; over 4,000 people work here each day.
Who: The UAE's Neuro Spinal Hospital and Radiosurgery Centre was first established in Jumeirah in 2002 by Dr. Abdul Karim Msaddi, as the first as the first "super-specialty" neuroscience hospital.
Why: With advanced diagnosis and robotics, the hospital will provide care across neuroscience, spine, orthopaedics and oncology for people residing in the UAE, as well as international patients.
Prof. Abdul Karim Msaddi, Chairman and Medical Director of the hospital, said: “We are proud to bring world-class healthcare services to Dubai and believe our next-generation hospital will be a game-changer for the emirate’s and the region’s medical industry.
"It will not only significantly increase the availability of specialist neuroscience and radiosurgery treatments and provide better patient care but help attract and develop local and international talent. Investing in the new centre represents our continued faith in the resilience of the region’s economy, as well as a testament to our ongoing drive towards healthcare innovation in the UAE.”